ACTG 5178

ACTG 5178

• 批准号: 7604606
• 负责人: Mark Sebastian Sulkowski
• 金额: $ 8.35万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604606
• 关键词: AIDS clinical trial group; Computer Retrieval of Information on Scientific Projects Database; Detection; Enrollment; Funding; Grant; Hepatitis C virus; Infection; Institution; Label; Liver Fibrosis; Maintenance; Maintenance Therapy; Phase; Rate; Research; Research Personnel; Resources; Ribavirin; Source; United States National Institutes of Health; Upper arm; design; peginterferon alfa-2a

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase II, open-label, two-arm, long-term maintenance therapy study. This trial is designed to study whether long-term maintenance with pegylated-interferon alfa-2a (PEG-IFN) reduces the rate of liver fibrosis progression in subjects with HCV/HIV co-infection who have failed to achieve or maintain HCV loads below the limit of detection during treatment with PEG-IFN plus ribavirin. Both HCV treatment na¿ve and previously treated subjects will be enrolled.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以出现在其他 CRISP 条目中 列出的机构是。 对于中心来说，它不一定是研究者的机构。 这是一项 II 期、开放标签、双组、长期维持治疗研究，旨在研究聚乙二醇化干扰素 α-2a (PEG-IFN) 的长期维持是否可以降低肝纤维化的发生率。在使用 PEG-IFN 加利巴韦林治疗期间未能达到或维持 HCV 负荷低于检测限的 HCV/HIV 合并感染受试者的进展 两种 HCV 治疗均不适用。之前接受过治疗的受试者将被纳入。